Comparative Pharmacology
Head-to-head clinical analysis: INDOMETHACIN SODIUM versus ZIPSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDOMETHACIN SODIUM versus ZIPSOR.
INDOMETHACIN SODIUM vs ZIPSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, antipyretic, and analgesic effects.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis involved in inflammation, pain, and fever. It has no significant inhibition of COX-1 at therapeutic doses.
Intravenous: 0.5 mg/kg every 12 hours or 0.25 mg/kg every 6 hours for patent ductus arteriosus closure in neonates. Oral/immediate-release: 25-50 mg two to three times daily. Extended-release: 75 mg once daily or 75 mg twice daily. Maximum daily dose: 200 mg.
50 mg orally three times daily
None Documented
None Documented
Terminal elimination half-life: 4.5 hours (range 2.6–11.2 hours); half-life may be prolonged in neonates, elderly, and renal impairment
2-4 hours (terminal); clinical context: short half-life necessitates frequent dosing for sustained relief; prolonged in hepatic impairment
Renal (60% as unchanged drug and metabolites, predominantly glucuronide conjugate); fecal (33%, primarily via biliary secretion); <5% unchanged in urine
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; remainder as glucuronide conjugates
Category D/X
Category C
NSAID
NSAID